In this article, we will list the 5 Healthcare Stocks Insiders Are Buying. Please visit 8 Healthcare Stocks Insiders Are Buying if you would like to see the extended list and the methodology behind it.
5. Aktis Oncology, Inc. (NASDAQ:AKTS)
On March 31, 2026, H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology, Inc. (NASDAQ:AKTS) to $33 from $30 previously and maintained a Buy rating on the shares. Robert Burns has said that the company’s pipeline is expected to advance and expand over the next twelve months.
On March 30, 2026, Aktis Oncology, Inc. (NASDAQ:AKTS) announced the FDA clearance of investigational new drug applications to begin a Phase 1b trial for AKY-25191, a miniprotein radioconjugate targeting B7-H3 across multiple solid tumors, including prostate and lung cancers.
Aktis Oncology, Inc. (NASDAQ:AKTS) said that AKY-2519 is its second clinical-stage miniprotein radioconjugate, while its lead program, AKY-1189, targeting Nectin-4, is already enrolling in a Phase 1b study, with both designed to deliver actinium-225 to tumor sites.
Aktis Oncology, Inc. (NASDAQ:AKTS) develops radiopharmaceutical therapies for solid tumors.
4. Veradermics, Incorporated (NYSE:MANE)
On March 30, 2026, Veradermics, Incorporated (NYSE:MANE) reported a Q4 net loss of $21.8M and ended the year with $141.9M in cash, cash equivalents, and marketable securities. CEO Reid Waldman said 2025 was a “landmark year,” highlighting progress in Phase 3 development of VDPHL01 and the company’s IPO, while noting expectations for two Phase 3 readouts in men, continued progress toward an NDA submission, and advancement of a Phase 3 trial for female pattern hair loss.
Earlier in March, Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage on Veradermics, Incorporated (NYSE:MANE) with an Overweight rating, noting the company’s focus on dermatology and its use of “validated biology” of minoxidil with optimized pharmacokinetics to improve efficacy and safety.
Similarly, Leerink initiated coverage on Veradermics, Incorporated (NYSE:MANE) with an Outperform rating and a $75 price target, highlighting the large market for hair loss treatments and positioning VDPHL01 as a potential best-in-class oral therapy for both men and women, supported by a hybrid marketing strategy combining telehealth and direct access.
Veradermics, Incorporated (NYSE:MANE) develops therapies for dermatologic and aesthetic conditions.
3. Sonida Senior Living, Inc. (NYSE:SNDA)
On April 7, 2026, Morgan Stanley raised the price target on Sonida Senior Living, Inc. (NYSE:SNDA) to $31 from $28 previously and maintained an Equal Weight rating on the shares. Morgan Stanley has said that the update reflects revised risk/reward following Q4 earnings and 2026 guidance, noting that Sonida Senior Living, Inc. (NYSE:SNDA) is in the early stages of a turnaround and could benefit from favorable senior housing demographics and limited supply.
On March 27, 2026, RBC Capital Markets initiated coverage on Sonida Senior Living, Inc. (NYSE:SNDA) with an Outperform rating and a $39 price target on the shares. RBC Capital has said that the acquisition of SNL Healthcare Properties is “transformative,” adding scale, earnings accretion, and reduced leverage, while positioning Sonida Senior Living, Inc. (NYSE:SNDA) to benefit from demand driven by aging demographics in a supply-constrained environment.
Sonida Senior Living, Inc. (NYSE:SNDA) owns and operates senior housing communities in the United States.
2. Phreesia, Inc. (NYSE:PHR)
On April 5, 2026, Wells Fargo lowered the price target on Phreesia, Inc. (NYSE:PHR) to $15 from $25 and maintained an Overweight rating. Wells Fargo said fiscal 2027 revenue guidance “decelerated sharply,” largely driven by the Network segment, citing valuation compression and slower growth, while noting recent Network channel checks were constructive.
On April 1, 2026, Citizens downgraded Phreesia to Market Perform from Outperform without a price target. Citizens said the updated fiscal 2027 revenue outlook was disappointing and raised concerns around the company’s ecosystem thesis, noting growth appears to be “sputtering out” in its largest subscription and related services segment.
On March 30, 2026, Phreesia reported Q4 adjusted EBITDA of $29.4M compared to $16.4M last year, with revenue of $127.1M versus the $126.6M consensus estimate. CEO Chaim Indig said the company achieved “critical financial milestones,” including positive GAAP net income of $2.3M and exceeding $100M in adjusted EBITDA and $50M in free cash flow for fiscal 2026.
Phreesia, Inc. (NYSE:PHR) provides SaaS-based software and payment solutions for the healthcare industry.
1. MapLight Therapeutics, Inc. (NASDAQ:MPLT)
On April 8, 2026, Needham initiated coverage of MapLight Therapeutics, Inc. (NASDAQ:MPLT) with a Buy rating and a $37 price target. Needham said the muscarinic class could be “disruptive” across multiple indications, including schizophrenia and Alzheimer’s disease psychosis, and noted ML-007C-MA may be “differentiated” from Cobenfy on tolerability and convenience, with potential to reach $1.5B in sales by 2035.
On April 7, 2026, TD Cowen initiated coverage of MapLight Therapeutics with a Buy rating, highlighting its pipeline targeting central nervous system and neuropsychiatric conditions. TD Cowen said the lead asset ML-007C-MA is positioned to improve on Cobenfy’s profile in schizophrenia, with a Phase II readout expected in Q3, and views the shares as undervalued based on this opportunity.
Last month, Canaccord initiated coverage of MapLight Therapeutics with a Buy rating and a $35 price target. Canaccord said the company’s focus on novel CNS therapeutics supports its schizophrenia opportunity and recommends buying the stock ahead of Phase 2 data for ML-007C-MA expected in Q3.
MapLight Therapeutics, Inc. (NASDAQ:MPLT) develops therapies for central nervous system disorders.
While we acknowledge the potential of MPLT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MPLT and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best Stocks That Beat Earnings Estimates and 10 Best 52-Week Low NASDAQ Stocks to Buy Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
